Generate Biomedicines (NASDAQ:GENB) Stock Falls 6% – Time to Sell?

Posted by Stanley Muller on Oct 13th, 2026

Generate Biomedicines Inc (NASDAQ:GENB – Get Free Report) shares fell 6% on Tuesday. The company traded as low as $12.95 and last traded at $13.01. 225,037 shares traded hands during trading, a decline of 73% from the average session volume of 843,769 shares. The stock had previously closed at $13.84.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Weiss Ratings raised Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 25th. Wall Street Zen raised Generate Biomedicines from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Generate Biomedicines in a research report on Monday, October 5th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $26.40.

Read Our Latest Analysis on Generate Biomedicines

Generate Biomedicines Stock Performance

The stock has a fifty day simple moving average of $15.56 and a two-hundred day simple moving average of $14.43. The stock has a market capitalization of $1.66 billion and a price-to-earnings ratio of -8.12.

Generate Biomedicines (NASDAQ:GENB – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter. Research analysts forecast that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.

Institutional Trading of Generate Biomedicines

Several institutional investors and hedge funds have recently made changes to their positions in the company. Braidwell LP purchased a new stake in Generate Biomedicines in the 2nd quarter valued at about $55,398,000. State Street Corp purchased a new position in Generate Biomedicines in the second quarter valued at about $8,883,000. The Manufacturers Life Insurance Company bought a new position in shares of Generate Biomedicines during the 2nd quarter valued at approximately $1,431,000. Bank of New York Mellon Corp bought a new stake in shares of Generate Biomedicines in the 2nd quarter worth approximately $967,000. Finally, Squarepoint Ops LLC bought a new position in Generate Biomedicines during the second quarter valued at $530,000.

About Generate Biomedicines

(Get Free Report)

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.